Paxlovid treatment in 20% of COVID-19 patients could avert 8

A study in the Emerging Infectious Diseases journal shows treating 20% of COVID-19 patients with Paxlovid could save up to 0.85 million lives and reduce the economic burden by US $170.17 billion in the US.

Related Keywords

United States , American , America , Dmitriy Prayzel , National Household Travel , Drug Administration , Public Health Impact Of Paxlovid As Treatment , Emerging Infectious Diseases , Stated States , Public Health Impact , Image Credit , Emergency Use Authorization , National Household Travel Survey , Coronavirus Disease Covid 19 , Antiviral Drug , Clinical Trial , Coronavirus , Drugs , Efficacy , Mmunodeficiency , Infectious Diseases , Pandemic , Public Health , Reproduction , Espiratory , Na , Cars , Ars Cov 2 , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Yndrome , Virus ,